DiaMedica Therapeutics Inc Dossier - Source-backed chat

DiaMedica Therapeutics Inc

DMACNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.98

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.35Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $450.3M

Enterprise Value $445.4M

Shares Outstanding 57.9M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

DiaMedica Therapeutics is a high-potential, clinical-stage biopharmaceutical company focused on severe ischemic diseases. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1 (KLK1) targeting acute ischemic stroke (AIS) and preeclampsia (PE). The investment thesis is anchored on the upcoming pivotal Phase 2/3 ReMEDy2 trial interim analysis in late 2026, which represents a major valuation inflection point. Furthermore, recent positive FDA feedback on the preeclampsia nonclinical program provides a clearer, cost-effective path toward a U.S. IND filing, while clinical trials in Canada and the UK are poised to begin in late 2026. Backed by a robust cash runway extending through 2027, DiaMedica offers an attractive risk-reward profile in maternal-fetal medicine and stroke care.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$11.00

Mean target$15.50

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The ReMEDy2 trial is stopped early for futility by the DSMB during the late 2026 interim analysis, or requires the maximum sample size of 728 patients, which severely strains the company's cash runway and necessitates highly dilutive financing. Additionally, the rat PK study fails to demonstrate sufficient exposure or enzymatic activity, leading the FDA to demand a completely new, expensive reproductive toxicity study, indefinitely delaying the U.S. preeclampsia program.

Base CaseCentral scenario

The ReMEDy2 trial successfully triggers its interim analysis by late 2026, with the DSMB recommending a sample size re-estimation within the planned 300-728 patient range, confirming the trial is on track and not futile. Concurrently, the rat PK study successfully addresses the FDA's requirements, paving the way for a U.S. IND in preeclampsia by early 2027. Clinical sites in Canada and the UK begin enrolling early-onset preeclampsia patients, validating DM199's therapeutic potential and driving steady upward valuation.

Bull CaseUpside scenario

The bullish thesis for DiaMedica centers on its lead asset, DM199 (rinvecalinase alfa), which has demonstrated disease-modifying potential in preeclampsia by addressing underlying endothelial dysfunction and improving placental blood flow. With a massive underserved market in maternal-fetal medicine, billion-dollar peak sales potential, and additional clinical development in acute ischemic stroke, the asset represents a potential game-changer with significant valuation upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

DM199 targets multi-billion dollar underserved markets with no currently approved disease-modifying therapies for preeclampsia or acute ischemic stroke.
Strong balance sheet with $51.3 million in cash and short-term investments as of March 31, 2026, providing a clear runway through 2027.
Pivotal ReMEDy2 trial has surpassed 75% of the enrollment required for the late 2026 interim analysis, offering a near-term high-impact catalyst.
Constructive FDA feedback on the preeclampsia program outlines a clear, low-cost path to a U.S. IND using existing reproductive toxicity data.

Key Investment Risks

Clinical development risk: The upcoming ReMEDy2 interim analysis could result in a futility determination or require a maximum sample size expansion.
Regulatory hurdles: The FDA may reject the rat PK study results, delaying the U.S. IND for preeclampsia.
Financing risk: As a pre-commercial biotech, DiaMedica will eventually require substantial capital raises to fund Phase 3 trials and commercial launch.

Thesis Invalidation Triggers

DSMB recommends stopping the ReMEDy2 trial for futility during the late 2026 interim analysis.
The rat PK study fails to satisfy the FDA's nonclinical requirements, blocking the U.S. IND path for DM199 in preeclampsia.
Severe safety or tolerability signals emerge in the ongoing preeclampsia trials in Canada or the UK.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.